Tailoring treatment of rectal adenocarcinoma: immunohistochemistry for predictive biomarkers
- PMID: 21233707
- DOI: 10.1097/CAD.0b013e3283433764
Tailoring treatment of rectal adenocarcinoma: immunohistochemistry for predictive biomarkers
Abstract
Over the past couple of decades, multimodality treatment for the management of resectable rectal cancer has substantially improved the outcome of affected patients. However, the broad and unpredictable response to tumor of patients with rectal cancer treated with preoperative chemoradiotherapeutic interventions shows that our understanding of the molecular events leading to radioresistance in patients affected with this malignancy remains sparse. Multiple attempts by individual molecular markers in gene array and tissue microarray studies have emerged with the goal of identifying predictors of a response to chemoradiation in patients with rectal cancer. In this report, we discuss the status of the markers currently available in an attempt to tailor specific targeted therapies for rectal cancer in the neoadjuvant setting.
Similar articles
-
[Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma].Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):602-5. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19102938 Chinese.
-
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61. doi: 10.1016/j.ijrobp.2007.02.018. Epub 2007 Apr 18. Int J Radiat Oncol Biol Phys. 2007. PMID: 17445998
-
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.Clin Oncol (R Coll Radiol). 2010 May;22(4):272-80. doi: 10.1016/j.clon.2010.01.001. Epub 2010 Feb 1. Clin Oncol (R Coll Radiol). 2010. PMID: 20117921
-
[Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].Orv Hetil. 2006 Oct 22;147(42):2011-20. Orv Hetil. 2006. PMID: 17165600 Review. Hungarian.
-
Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.Eur J Surg Oncol. 2006 Feb;32(1):55-64. doi: 10.1016/j.ejso.2005.09.010. Epub 2005 Dec 1. Eur J Surg Oncol. 2006. PMID: 16324817 Review.
Cited by
-
Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma.Oncotarget. 2015 Oct 27;6(33):34321-8. doi: 10.18632/oncotarget.5761. Oncotarget. 2015. PMID: 26416417 Free PMC article.
-
Treatment of locally advanced rectal cancer: controversies and questions.World J Gastroenterol. 2012 Oct 21;18(39):5521-32. doi: 10.3748/wjg.v18.i39.5521. World J Gastroenterol. 2012. PMID: 23112544 Free PMC article. Review.
-
The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.Langenbecks Arch Surg. 2012 Apr;397(4):543-55. doi: 10.1007/s00423-012-0929-5. Epub 2012 Mar 2. Langenbecks Arch Surg. 2012. PMID: 22382702 Free PMC article. Review.
-
High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer.J Cancer Res Clin Oncol. 2020 Jan;146(1):105-115. doi: 10.1007/s00432-019-03099-4. Epub 2019 Nov 28. J Cancer Res Clin Oncol. 2020. PMID: 31781865
-
Overexpression of SYNGAP1 suppresses the proliferation of rectal adenocarcinoma via Wnt/β-Catenin signaling pathway.Discov Oncol. 2024 Apr 29;15(1):135. doi: 10.1007/s12672-024-00997-z. Discov Oncol. 2024. PMID: 38679635 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
